Recent studies suggest that targeting CSCs may provide an exciting avenue to enhance the effectiveness of immunotherapy.25 To further assess the impact of LIMP-2 on the potential efficacy of immunotherapy, we evaluated the TIDE algorithm using the TCGA-HNSCC dataset (Fig. 8a). The gene discussed is SCARB2; the disease is head and neck squamous cell carcinoma.